

Pernille Ravn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1797783/pernille-ravn-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

4,194
citations

35
h-index

62
g-index

111
ext. papers

4,656
ext. citations

4.5
avg, IF

4.98
L-index

#	Paper	IF	Citations
106	Prevalence of hepatitis B and C at a major tuberculosis centre in Denmark. <i>Infectious Diseases</i> , 2021 , 53, 196-200	3.1	0
105	Higher blood pressure in normal weight women with PCOS compared to controls. <i>Endocrine Connections</i> , 2021 , 10, 154-163	3.5	2
104	MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people. <i>European Journal of Endocrinology</i> , 2021 , 185, R49-R63	6.5	5
103	Clinical usefulness of a urine dipstick to detect ethyl glucuronide (EtG): A quantitative clinical study in healthy young female volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 709-715	3.1	0
102	Novel phenotype of syndromic premature ovarian insufficiency associated with TP63 molecular defect. <i>Clinical Genetics</i> , 2020 , 97, 779-784	4	6
101	Relationship between a uterine fibroid diagnosis and the risk of adverse obstetrical outcomes: a cohort study. <i>BMJ Open</i> , 2020 , 10, e032104	3	8
100	Uterine fibroids increase time to pregnancy: a cohort study. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020 , 25, 37-42	1.8	6
99	Do-not-resuscitate orders in patients with community-acquired pneumonia: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 201	3.5	3
98	Management and monitoring of opioid use in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020 , 99, 7-15	3.8	4
97	The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia. A Prospective Cohort Study. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1518-1526	4.7	5
96	Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia?. <i>Infectious Diseases</i> , 2019 , 51, 340-347	3.1	13
95	Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe. <i>PLoS ONE</i> , 2019 , 14, e0226074	3.7	13
94	Motivational interviewing in obese women with polycystic ovary syndrome - a pilot study. <i>Gynecological Endocrinology</i> , 2019 , 35, 76-80	2.4	5
93	Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe 2019 , 14, e0226074		
92	Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe 2019 , 14, e0226074		
91	Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe 2019 , 14, e0226074		
90	Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe 2019 , 14, e0226074		

89	Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS. <i>Endocrine Connections</i> , 2018 , 7, 479-489	3.5	5
88	Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2018 , 34, 859-863	2.4	7
87	Fertility after uterine artery embolization of fibroids: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 297, 13-25	2.5	52
86	Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. <i>Fertility and Sterility</i> , 2017 , 107, 788-795.e2	4.8	60
85	Magnetic Resonance Signal Intensity Ratio Measurement Before Uterine Artery Embolization: Ability to Predict Fibroid Size Reduction. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1839-1844	2.7	9
84	The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. <i>Human Reproduction</i> , 2017 , 32, 2279-2286	5.7	27
83	Readmission to hospital of medical patients - A cohort study. <i>European Journal of Internal Medicine</i> , 2017 , 46, 19-24	3.9	8
82	Uterine fibroid embolization with acrylamido polyvinyl microspheres: prospective 12-month clinical and MRI follow-up study. <i>Acta Radiologica</i> , 2017 , 58, 952-958	2	6
81	Clinical Long-Term Outcome and Reinterventional Rate After Uterine Fibroid Embolization with Nonspherical Versus Spherical Polyvinyl Alcohol Particles. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 204-9	2.7	8
80	Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016 , 95, 1235-1243	3.8	23
79	Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndrome. <i>Human Reproduction</i> , 2016 , 31, 1105-12	5.7	9
78	Performance of Interferon-Gamma and IP-10 Release Assays for Diagnosing Latent Tuberculosis Infections in Patients with Concurrent Malaria in Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016 , 94, 728-35	3.2	5
77	Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 72.e1-8	6.4	15
76	Gynecological cancer alarm symptoms: is contact with specialist care associated with lifestyle and socioeconomic status? A population-based study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016 , 95, 976-83	3.8	6
75	Should we individualize lipid profiling in women with polycystic ovary syndrome?. <i>Human Reproduction</i> , 2016 , 31, 2791-2795	5.7	5
74	Specific and unspecific gynecological alarm symptoms--prevalence estimates in different age groups: a population-based study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015 , 94, 191-7	3.8	16
73	Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015 , 94, 204-11	3.8	26
72	Prevalence of substance abuse in pregnancy among Danish women. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015 , 94, 215-9	3.8	7

71	Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	8
70	Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 677-84	3.8	14
69	False-negative interferon- γ release assay results in active tuberculosis: a TBNET study. <i>European Respiratory Journal</i> , 2015 , 45, 279-83	13.6	27
68	Pharmacokinetic-pharmacodynamic modelling of the analgesic and antihyperalgesic effects of morphine after intravenous infusion in human volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014 , 115, 257-67	3.1	7
67	Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2014 , 29, 1773-9	5.7	26
66	Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2584-91	5.6	55
65	Colposcopic photography of genital injury following sexual intercourse in adults. <i>Forensic Science, Medicine, and Pathology</i> , 2013 , 9, 24-30	1.5	7
64	Hormone replacement therapy and risk of glioma: a nationwide nested case-control study. <i>Cancer Epidemiology</i> , 2013 , 37, 876-80	2.8	8
63	Hormone replacement therapy increases the risk of cranial meningioma. <i>European Journal of Cancer</i> , 2013 , 49, 3303-10	7.5	25
62	Patterned genital injury in cases of rape--a case-control study. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2013 , 20, 525-9	1.7	21
61	Effects of exercise and group counselling on body composition and VO ₂ max in overweight women with polycystic ovary syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013 , 92, 272-7	3.8	17
60	Motivational interviewing: a part of the weight loss program for overweight and obese women prior to fertility treatment. <i>Gynecological Endocrinology</i> , 2013 , 29, 839-42	2.4	11
59	The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012 , 91, 1173-6	3.8	21
58	Nature, frequency and duration of genital lesions after consensual sexual intercourse--implications for legal proceedings. <i>Forensic Science International</i> , 2012 , 219, 50-6	2.6	37
57	Detection of spermatozoa following consensual sexual intercourse. <i>Forensic Science International</i> , 2012 , 221, 137-41	2.6	17
56	Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 white patients with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2012 , 28, 170-4	2.4	22
55	Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome. <i>Hormone and Metabolic Research</i> , 2012 , 44, 694-8	3.1	18
54	Combined oral contraceptives influence on weight, body composition, height, and bone mineral density in girls younger than 18 years: a systematic review. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012 , 17, 245-53	1.8	20

53	Supportive relationships--psychological effects of group counselling in women with polycystic ovary syndrome (PCOS). <i>Communication and Medicine</i> , 2012 , 9, 125-31	0	12
52	Significant effect of raloxifene on bone in hemodialysis patients. <i>International Journal of Endocrinology and Metabolism</i> , 2012 , 10, 636-7	1.8	
51	Long-term follow up after uterine artery embolization for symptomatic uterine leiomyomas. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011 , 90, 1281-3	3.8	17
50	Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. <i>Clinical Endocrinology</i> , 2010 , 73, 732-8	3.4	47
49	Postmenopausal endometriosis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007 , 86, 1158-64	3.8	45
48	Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. <i>Maturitas</i> , 2006 , 53, 184-90	5	29
47	What can be learned from the levormeloxifene experience?. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006 , 85, 135-42	3.8	15
46	Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. <i>Maturitas</i> , 2005 , 50, 78-85	5	20
45	An outpatient regimen of combined oral mifepristone 400 mg and misoprostol 400 microg for first-trimester legal medical abortion. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2005 , 84, 1098-102	3.8	4
44	Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4879-85	5.6	66
43	High frequency of congenital thrombophilia in women with pathological pregnancies?. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004 , 83, 808-17	3.8	17
42	Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. <i>Osteoporosis International</i> , 2004 , 15, 168-74	5.3	31
41	Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. <i>Climacteric</i> , 2004 , 7, 103-11	3.1	41
40	Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. <i>Bone</i> , 2004 , 34, 728-35	4.7	134
39	The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. <i>Bone</i> , 2004 , 35, 1216-21	4.7	31
38	Changes in bone density and turnover after alendronate or estrogen withdrawal. <i>Menopause</i> , 2004 , 11, 622-30	2.5	83
37	Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. <i>Menopause</i> , 2004 , 11, 337-42	2.5	20
36	Visceral fat is more important than peripheral fat for endometrial thickness and bone mass in healthy postmenopausal women. <i>American Journal of Obstetrics and Gynecology</i> , 2003 , 188, 349-53	6.4	26

35	Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. <i>Bone</i> , 2003 , 33, 301-7	4.7	92
34	Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. <i>Bone</i> , 2003 , 33, 150-8	4.7	55
33	Measurement precision and normal range of endometrial thickness in a postmenopausal population by transvaginal ultrasound. <i>Ultrasound in Obstetrics and Gynecology</i> , 2002 , 20, 492-5	5.8	14
32	Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. <i>Bone</i> , 2002 , 30, 320-4	4.7	37
31	Depression: a major, unrecognized risk factor for osteoporosis?. <i>Trends in Endocrinology and Metabolism</i> , 2001 , 12, 198-203	8.8	130
30	Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1492-7	5.6	67
29	Relation between body composition and biochemical markers of bone turnover among early postmenopausal women. <i>Journal of Clinical Densitometry</i> , 2000 , 3, 365-71	3.5	5
28	Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1492-1497	5.6	65
27	Long-Term Prevention of Bone Loss. <i>Annals of Internal Medicine</i> , 2000 , 133, 72	8	
26	Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1999 , 131, 935-42	8	125
25	Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1622-7	6.3	282
24	Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. <i>Osteoporosis International</i> , 1999 , 9, 277-83	5.3	13
23	Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. <i>Bone</i> , 1999 , 24, 237-44	4.7	124
22	Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2363-2368	5.6	98
21	Evidence that increased calcium intake does not prevent early postmenopausal bone loss. <i>Clinical Therapeutics</i> , 1998 , 20, 933-44	3.5	29
20	Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. <i>Bone</i> , 1998 , 22, 559-64	4.7	59
19	Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group. <i>International Journal of Epidemiology</i> , 1998 , 27, 479-83	7.8	46
18	Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. <i>New England Journal of Medicine</i> , 1998 , 338, 485-92	59.2	428

17	Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. <i>Annals of Internal Medicine</i> , 1998 , 128, 253-61	8	180
16	Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. <i>Clinical Chemistry</i> , 1998 , 44, 2290-2300	5.5	130
15	Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. <i>Bone</i> , 1997 , 20, 63-7	4.7	17
14	A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. <i>Osteoporosis International</i> , 1997 , 7, 488-95	5.3	48
13	High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. <i>Calcified Tissue International</i> , 1997 , 60, 255-60	3.9	51
12	High bone turnover is associated with low bone mass in both pre- and postmenopausal women. <i>Bone</i> , 1996 , 19, 291-8	4.7	69
11	The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. <i>Bone</i> , 1996 , 19, 527-33	4.7	139
10	Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) Study Group. <i>Calcified Tissue International</i> , 1996 , 59, 339-43	3.9	91
9	A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. <i>American Journal of Clinical Nutrition</i> , 1996 , 64, 354-60	7	62
8	Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC Study. <i>Osteoporosis International</i> , 1996 , 6, 308-13	5.3	23
7	Bone mineral density in immigrants from southern China to Denmark. A cross-sectional study. <i>European Journal of Endocrinology</i> , 1996 , 134, 163-7	6.5	11
6	Early postmenopausal diminution of forearm and spinal bone mineral density: a cross-sectional study. <i>Osteoporosis International</i> , 1995 , 5, 35-8	5.3	34
5	Insulin-like growth factors I and II in healthy women with and without established osteoporosis. <i>European Journal of Endocrinology</i> , 1995 , 132, 313-9	6.5	46
4	Lack of influence of simple premenopausal hysterectomy on bone mass and bone metabolism. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 172, 891-5	6.4	24
3	Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1975-80	6.3	70
2	Total and regional body-composition changes in early postmenopausal women: age-related or menopause-related?. <i>American Journal of Clinical Nutrition</i> , 1994 , 60, 843-8	7	128
1	Osteosynthesis of medial humeral epicondyle fractures in children. 8-year follow-up of 33 cases. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 1994 , 65, 439-41	4.3	36